Clinical Trial Detail

NCT ID NCT02507570
Title Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Carolina Research Professionals, LLC
Indications

prostate cancer

Therapies

Enzalutamide

Radium Ra 223 dichloride

Age Groups: adult

No variant requirements are available.